This is a working overview of glass transition, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
Stability of a lyophilized product depends on its glass transition temperature, the temperature at which the amorphous cake transitions from a glassy to a rubbery state. Storage below this temperature minimizes molecular mobility and slows chemical degradation. If the storage temperature exceeds the glass transition temperature, the cake may collapse, shrink, or become sticky. Accelerated stability studies at elevated temperatures and humidity help predict shelf life, but they do not always reflect real-time behavior. Residual moisture content also plays a critical role in long-term stability.
Reconstitution involves adding a suitable diluent, often sterile water or a buffer, to the dried cake. Gentle swirling or inversion helps dissolve the material without creating excessive foam. The time required for complete dissolution can range from seconds to several minutes and depends on the cake structure and the diluent. Improper reconstitution, such as vigorous shaking or using the wrong diluent, can cause protein aggregation or loss of activity. After reconstitution, the product may have a limited shelf life and should be used according to its labeling.
Regulatory expectations for lyophilized products focus on consistent manufacture and documented stability. Batches are often monitored for moisture, appearance, potency, and sterility where applicable. Process parameters such as shelf temperature, chamber pressure, and drying time are recorded and controlled within validated ranges. Open questions remain about how best to predict long-term stability from short accelerated studies, especially for complex biologics. Variations in freezing rate and ice crystal size can produce differences that are not always visible but may affect performance.
After drying, a lyophilized product is usually sealed under vacuum or an inert gas to limit moisture uptake. Residual water content is measured because small changes can alter chemical stability and cake appearance. Storage temperature depends on the material; many biological products are kept at 2–8 °C, while some require −20 °C or colder. Exposure to ambient humidity during handling can cause the porous solid to absorb water and collapse. Container closures and stoppers are therefore selected for low moisture transmission and compatibility.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white porous cake | Color depends on formulation. |
| Typical storage temperature | 2–8 °C | Refrigerated for many biologics. |
| Residual moisture | <1% to 3% | Low moisture improves stability. |
| Container | Sealed glass vial | Often with rubber stopper and aluminum crimp. |
| Reconstitution time | Seconds to minutes | Varies with cake density and diluent. |
Quality control for freeze-dried lots combines visual inspection with instrumental tests. Cake appearance, color, and shrinkage are recorded against a reference, while residual moisture is measured by Karl Fischer titration or loss on drying. Thermal analysis can reveal phase transitions and crystallization events, and X-ray diffraction distinguishes amorphous from crystalline solids. Microbiological tests and container closure integrity checks are also routine for sterile products. Analytical methods must be validated for the matrix, because excipients and low moisture can affect accuracy. Open questions include how best to predict long-term stability from short-term data.
Lyophilized solids are often hygroscopic, so handling occurs in controlled low-humidity areas or glove boxes when the material is exposed. Vials remain sealed with elastomeric stoppers and aluminum crimps until use, because airborne moisture can raise residual water and shorten shelf life. The porous cake is fragile and may crack, shrink, or powder during transport. Personnel typically avoid repeated warming and cooling of sealed units, which can draw moisture through closures. These practices aim to preserve the low water content achieved during drying.
Quality control for lyophilized products includes appearance, cake structure, reconstitution time, pH, residual moisture, and potency. Residual moisture is a key attribute because excess water can reduce stability, while excessively low moisture may cause structural changes or aggregation in some systems. Stability studies compare real-time and accelerated conditions to estimate shelf life. Analytical methods must be validated for the specific matrix, container, and moisture range. Sterility and container integrity are also monitored for sterile products.
Handling practices aim to prevent moisture ingress and mechanical damage. Vials should remain stoppered and crimped until use, and reconstitution should follow the labeled diluent and volume. Shipping may involve temperature-controlled containers and desiccants, but direct contact between desiccant and product is avoided. Regulatory guidance expects documented storage conditions, excursion assessments, and stability commitments. Open questions remain about how best to predict long-term stability from short accelerated studies for every formulation class.
After lyophilization, the product is usually a porous cake or powder with a large internal surface area. This structure can absorb moisture quickly if exposed to humid air, so vials are sealed under vacuum or an inert gas. Moisture uptake may lower the glass transition temperature of the dried matrix and accelerate chemical or physical degradation. Storage conditions therefore depend on the formulation, container, and intended shelf life. Some products remain stable at room temperature, while others require refrigeration or freezing.
Lyophilized products are typically stored as sealed solids in vials or syringes. Moisture ingress is a major concern because many dried cakes are hygroscopic and can lose stability when exposed to humid air. Storage temperature depends on the formulation; some products are kept refrigerated, while others are stable at room temperature. Container closure integrity and headspace moisture are often monitored. Light protection may also be required for some photosensitive materials.
Quality control for lyophilized materials includes visual inspection, residual moisture measurement, and reconstitution testing. Cake appearance can reveal process problems such as collapse, shrinkage, or meltback, although appearance alone does not prove potency. Residual moisture is commonly measured by Karl Fischer titration or by loss on drying. Reconstitution time is checked because a slow or incomplete dissolve can indicate a change in pore structure. Stability studies track these attributes over time under defined temperature and humidity conditions.
=== 5 March === Two Ukrainian pilots were in the United States to see how long it would take them to learn how to fly attack aircraft including the F-16. Another 10 pilots had been approved for similar testing in the United States but were yet to arrive.
=== Musculoskeletal === Evidence does not support a benefit in delayed-onset muscle soreness. It may be useful for muscle pain and injuries. A 2008 Cochrane Library review concluded that LLLT has insufficient evidence for treatment of nonspecific low back pain, a finding echoed in a 2010 review of chronic low back pain. A 2015 review found benefit in nonspecific chronic low-back pain. LLLT may be useful in the treatment of both acute and chronic neck pain. In 2013, however, a systematic review and meta-analysis of LLLT for neck pain indicated that the benefit was not of significant importance and that the evidence had a high risk of bias. In a study testing the efficacy of low-level laser therapy treating plantar fasciitis found that LLLT significantly reduces pain in lower extremity tendinopathy and plantar fasciitis in the short and medium terms. The same study also stated that while comparing the effect of LLLT to that of therapeutic ultrasound in persons with patellar tendinopathy, and they found a statistically significant effect in favor of LLLT, both on pain reduction and function. There are tentative data that LLLT is useful in the short-term treatment of pain caused by rheumatoid arthritis, and possibly chronic joint disorders. Research that compared the effects of LLLT against other treatments, sham treatments, or no treatment at all, and randomized adult patients with rheumatoid arthritis to receive it were considered.
For the use of hormone antagonists in cancer, see hormonal therapy (oncology) A hormone antagonist is a molecule, produced either synthetically or endogenously, that binds to a specific hormone receptor to block the effect or synthesis of that hormone. There are many types of hormone antagonists, such as gonadotropin-releasing hormone (GnRH) antagonists, estrogen antagonists, and androgen antagonists. Organisms may use hormone antagonists to modify the action of their hormone receptors. For example, ghrelin is a hormone that stimulates appetite and growth hormone release by activating the growth hormone secretagogue receptor (GHSR). LEAP2 was found to be a peptide hormone synthesized by the liver and small intestine that blocks the GHSR activation by ghrelin, thereby reducing appetite. Synthetically produced hormone antagonists can also be used as anticancer treatments for hormone-sensitive cancers like breast cancer and prostate cancer.
== Early life and education == Olabisi is from Plainfield, New Jersey. She grew up wanting to be an astronaut. Her mentors have been her graduate school and postdoctoral advisors, including Profs. John Taylor, Ray Vanderby, Jr, and Jennifer L. West, as well as individuals not directly involved in her training, such as Mae Jemison. She studied aerospace engineering at Massachusetts Institute of Technology. She moved to the University of Michigan for her Masters research. She completed her doctoral work at University of Wisconsin–Madison. She was awarded the National Science Foundation GSK-12 Award.
In December 1940, Franz Simon at Oxford wrote his Estimate of the size of an actual separation plant." Simon proposed gaseous diffusion as the best method for uranium isotope separation. On 28 March 1941, Emilio Segré and Glen Seaborg reported on the "strong indications that 239Pu undergoes fission with slow neutrons." This meant chemical separation was an alternative to uranium isotope separation. Instead, a nuclear reactor fueled with ordinary uranium could produce a plutonium isotope as a nuclear explosive substitute for 235U. In May, they demonstrated the cross section of plutonium was 1.7 times that of U235. When plutonium's cross section for fast fission was measured to be ten times that of U238, plutonium became a viable option for a bomb. In October 1941, MAUD released its final report to the U.S. Government. The report stated, "We have now reached the conclusion that it will be possible to make an effective uranium bomb...The material for the first bomb could be ready by the end of 1943..." In November 1941, John Dunning and Eugene T. Booth were able to demonstrate the enrichment of uranium through gaseous barrier diffusion. On 27 November, Bush delivered to third National Academy of Sciences report to Roosevelt. The report, amongst other things, called for parallel development of all isotope-separation systems. On 6 December, Bush and Conant reorganized the Uranium Committee's tasks, with Harold Urey developing gaseous diffusion, Lawrence developing electromagnetic separation, Eger V.
Sources: en.wikipedia.org
Ricin toxin vaccines have emerged as a focus in biodefense research. Two recombinant A subunit (RTA)-based vaccines, RiVax and RVEc (also known as RTA1-33/44-198), have completed Phase I clinical trials, and were found to be safe. These vaccines are based on modified versions of the ricin toxin A-chain, designed to reduce toxicity while maintaining immunogenicity. A biopharmaceutical company called Soligenix, Inc. licensed an anti-ricin vaccine called RiVax from Vitetta et al. at UT Southwestern. The vaccine was found safe and immunogenic in mice, rabbits, and humans. Two successful clinical trials were completed. Soligenix was issued a US patent for Rivax. The ricin vaccine candidate was granted orphan drug status in the US and the EEC and, as of 2019, was in clinical trials in the US. Grants from the National Institute of Allergy and Infectious Diseases and the US Food and Drug Administration supported development of the vaccine candidate.
== Toxicity == DBNPA exhibits various degrees of toxicity like acute oral toxicity, dermal toxicity and inhalation toxicity while it is stable under normal conditions of use. Contact with strong amines should however be avoided including bases, oxidizing agents and reducing agents. DBNPA is corrosive to mild steel, iron and aluminum. The creation of dust when handling DBNPA should be avoided and precautionary measures against electrostatic discharges should be taken. Avoid heat, open flames and other potential sources of ignition when handling DBNPA. Additionally, DBNPA is corrosive to the eyes. It is moderately toxic by oral or inhalation routes and slightly toxic by the dermal route. DBNPA can kill skin tissue in rabbits when administered at high doses for a prolonged period of time. DBNPA is also a skin sensitizer. In a toxicity study using rats, DBNPA caused breathing difficulty associated with lung or heart disease, as well as weight loss and several deaths at higher doses. When applied to the skin of rats in another study, DBNPA caused changes in body chemistry and dermal irritation at the higher doses. DBNPA is a developmental toxicant in rabbits. It was shown to cause structural alterations (retarded ossification of several fetal skeleton elements) at a maternally non-toxic dose level. DBNPA is not mutagenic. The United States Environmental Protection Agency (EPA) has received several human incident reports in which eye, throat and respiratory irritation, runny nose and headache resulted from spills or misuse of DBNPA.
=== Main === Jean Smart as Deborah Vance, a revered Las Vegas stand-up comedian decades into her career Hannah Einbinder as Ava Daniels, a 25-year-old down-on-her-luck comedy writer forced to leave Los Angeles and work with Deborah Vance Carl Clemons-Hopkins as Marcus, the loyal workaholic COO of Deborah's company
== Properties and ingredients == In a study funded by Aquaphor's parent company, it was found that their "Healing Ointment" product was associated with (but did not cause) decreased redness around the wound but did not perform better than other products clinically. Aquaphor is not comedogenic and does not contain any fragrances, preservatives, or dyes. Unlike Vaseline (100% petrolatum), which is occlusive, Aquaphor (41% petrolatum) claims to form a semi-occlusive barrier on the skin. This theoretically enables the transmission of water and oxygen, which is important for wound healing and the formation of a protective moist healing environment. However, no studies have been conducted using this brand to test these healing claims.
By stimulating this angio- and vasculogenesis, CGB provides the placenta with a sufficient maternal blood supply, thus providing the embryo with the crucial nutrition it needs during its invasion of the uterine endometrium. As a more comprehensive overview: CGB promotes progesterone production by corpus luteal cells, promotes angiogenesis in uterine vasculature, promotes the fusion of cytotrophoblast cells and the subsequent differentiation to make syncytiotrophoblast cells, promotes the blockage of any immune or macrophage action by the maternal immune system on foreign invading placental cells, initiates proper and appropriate uterine growth parallel to fetal growth, suppresses any myometrial contractions during the course of pregnancy, stimulates growth and differentiation of the umbilical cord, prepares the endometrium for the approaching embryo implantation, acts on a receptor in mother's brain causing severe nausea and vomiting, and has also been shown to promote the growth of fetal organs during pregnancy.
Sources: en.wikipedia.org
Lyophilized products should be stored in airtight containers, protected from moisture and light, at the temperature specified by the manufacturer. Many require refrigeration at 2–8 °C, while some need frozen storage. Always check the product label for specific conditions.
Moisture can cause the porous cake to collapse, increase molecular mobility, and accelerate chemical degradation. It may also promote microbial growth if the product lacks preservatives. Proper sealing and handling are essential to maintain stability.
Some formulations contain labile biological molecules that degrade even in the dry state at higher temperatures. Others have a low glass transition temperature, meaning the cake can soften or collapse at room temperature. Cold storage reduces molecular motion and slows degradation.
Most are held in sealed containers at controlled temperatures, often 2–8 °C, while some require frozen storage. Protection from moisture and light helps preserve the dry matrix. Exact conditions are set by the manufacturer or study protocol.